Development asset linked to Guangzhou Virotech Pharmaceutical in public FDA and regional records.
pharma · Transfusion Dependent Beta-Thalassaemia · Labor Induction
Guangzhou Virotech Pharmaceutical
Guangzhou Virotech Pharmaceutical Co.,
Guangzhou Virotech Pharmaceutical drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 2
- Patents
- 0
Guangzhou Virotech Pharmaceutical pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Guangzhou Virotech Pharmaceutical drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Copper.
- Target
- Copper
- Mechanism
- Copper chelating agent